Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00600873 · ClinicalTrials.gov registry record · Phase 1
R(+)PPX High Dose Treatment of ALS
A Phase 1 study of Amyotrophic Lateral Sclerosis, sponsored by Bennett, James P., Jr., M.D., Ph.D..
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT00600873: Completed Phase 1 study of Amyotrophic Lateral Sclerosis, sponsored by Bennett, James P., Jr., M.D., Ph.D..
NCT00600873 is a Phase 1 study of Amyotrophic Lateral Sclerosis that has completed, run by Bennett, James P., Jr., M.D., Ph.D.. The registered enrollment target is 10 participants, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00600873, a Phase 1 study of Amyotrophic Lateral Sclerosis, has completed, sponsored by Bennett, James P., Jr., M.D., Ph.D..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
R(+)pramipexole is administered in escalating doses to patients with early ALS. Plasma and spinal fluid levels of R(+)PPX are monitored, in addition to biochemical markers of oxidative stress.
Conditions Studied
Interventions
- DRUG R(+) pramipexole dihydrochloride monohydrate
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
What the finished NCT00600873 record still lists
NCT00600873 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which R(+) pramipexole dihydrochloride monohydrate is the first listed.
NCT00600873 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT00600873 about?
NCT00600873 is a clinical study titled "R(+)PPX High Dose Treatment of ALS". R(+)pramipexole is administered in escalating doses to patients with early ALS. Plasma and spinal fluid levels of R(+)PPX are monitored, in addition to biochemical markers of oxidative stress.
What is the current status of trial NCT00600873?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2007-08. Estimated completion is 2009-01.
What conditions does trial NCT00600873 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT00600873?
The interventions under investigation include: R(+) pramipexole dihydrochloride monohydrate (DRUG).
Who is sponsoring clinical trial NCT00600873?
This trial is sponsored by Bennett, James P., Jr., M.D., Ph.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00600873 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00600873's enrollment target sits among peer trials
10 91st of 102 higher than 12 of 102 other Amyotrophic Lateral Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS
RECRUITING · Phase 1
-
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
RECRUITING · Phase 1
-
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
ACTIVE NOT RECRUITING · Phase 1
-
Regulatory T Cells for Amyotrophic Lateral Sclerosis
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia